Beam Therapeutics (MEX:BEAM) YoY EPS Growth: -9.35% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
63 GF Score
Price MXN500.00
GF Value MXN428.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics YoY EPS Growth?

Beam Therapeutics MEX:BEAM 63 YoY EPS Growth is -9.35% as of Jun. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 63/100 and a GF Value™ of MXN428.06 (Modestly Overvalued). The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Beam Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 was -9.35%.

Beam Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was MXN-20.59.

Beam Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics YoY EPS Growth Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only -42.02 31.98 63.74 -227.16 84.73

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.41 12.41 284.55 34.79 -9.35
MEX:BEAM
63GF Score
Beam Therapeutics Inc MEX:BEAM
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Beam Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-14.585--95.519)/ | -95.519 |
=84.73 %

Beam Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-20.59--18.829)/ | -18.829 |
=-9.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -9.35% mean?
Beam Therapeutics (MEX:BEAM) has a YoY EPS Growth of -9.35% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Beam Therapeutics and its competitors.
Is Beam Therapeutics' YoY EPS Growth too high?
Beam Therapeutics' current YoY EPS Growth is -9.35%. Overall, Beam Therapeutics has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' YoY EPS Growth compare to MBX and ARQT?
Beam Therapeutics' YoY EPS Growth of -9.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current YoY EPS Growth is -9.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN428.06, compared to a current price of MXN500.00 — trading 16.8% above its estimated fair value. The current YoY EPS Growth is -9.35%. Beam Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current YoY EPS Growth is -9.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN500.00 is trading 16.8% above its estimated GF Value™ of MXN428.06. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • YoY EPS Growth: -9.35%
  • GF Value™: MXN428.06 vs. price of MXN500.00 (16.8% above fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
63GF Score

Get the complete analysis for MEX:BEAM

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN500.00
Price
MXN428.06
GF Value